The Golden Era of GLP-1 Drugs GLP-1 RAs are entero-pancreatic hormone-based treatments, first approved in 2005 for type 2 diabetes (T2D), and now commonly prescribed for weight loss and reduction of atherosclerotic cardiovascular (CV) risk in patients with T2D
The reason GLP-1 telehealth platforms exist is the same reason patients are using them at scale: traditional routes to prescription weight loss medication are expensive, slow, often unavailable, and structured around insurance systems that have historically classified obesity treatment as an elective rather than a chronic metabolic condition requiring clinical management - a classification that major professional societies have spent years working to overturn
In cases of severe nausea or vomiting, its important to contact a healthcare provider, as these side effects could indicate the need for a medication adjustment
Medical Disclaimer The information provided on this website is for general informational purposes only and does not constitute medical advice, diagnosis, or treatment
doi: 10.1016/j.freeradbiomed.2020.07.026 16 KremerDMNelsonBSLinLYaroszELHalbrookCJKerkSAet al